Strategic Advisors LLC grew its position in Celgene Corporation (NASDAQ:CELG) by 1.8% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,702 shares of the biopharmaceutical company’s stock after buying an additional 48 shares during the period. Strategic Advisors LLC’s holdings in Celgene Corporation were worth $351,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in CELG. Capital Counsel LLC NY raised its position in shares of Celgene Corporation by 0.4% in the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 6 shares during the last quarter. Sowell Financial Services LLC raised its position in shares of Celgene Corporation by 0.5% in the 1st quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 13 shares during the last quarter. South Texas Money Management Ltd. raised its position in shares of Celgene Corporation by 0.6% in the 1st quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 15 shares during the last quarter. Flagship Harbor Advisors LLC raised its position in shares of Celgene Corporation by 0.9% in the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after purchasing an additional 18 shares during the last quarter. Finally, Savant Capital LLC raised its position in shares of Celgene Corporation by 0.9% in the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 20 shares during the last quarter. Institutional investors and hedge funds own 79.16% of the company’s stock.

In other Celgene Corporation news, Director Michael D. Casey sold 9,250 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total value of $1,286,027.50. Following the completion of the transaction, the director now owns 9,250 shares in the company, valued at $1,286,027.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Terrie Curran sold 1,727 shares of the stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders have sold 20,227 shares of company stock valued at $2,843,956 in the last 90 days. Company insiders own 0.95% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Celgene Corporation (CELG) Stake Increased by Strategic Advisors LLC” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/celgene-corporation-celg-stake-increased-by-strategic-advisors-llc/1711121.html.

Several equities analysts recently commented on CELG shares. BMO Capital Markets increased their price objective on shares of Celgene Corporation from $148.00 to $155.00 and gave the company an “outperform” rating in a research report on Friday. Leerink Swann reissued an “outperform” rating and set a $160.00 price target (up from $150.00) on shares of Celgene Corporation in a research report on Friday, July 28th. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $170.00 price target on shares of Celgene Corporation in a research report on Friday, October 20th. Vetr raised shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $144.39 price target for the company in a research report on Monday, October 23rd. Finally, Cann reissued a “buy” rating on shares of Celgene Corporation in a research report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $139.87.

Shares of Celgene Corporation (NASDAQ CELG) opened at $104.10 on Friday. Celgene Corporation has a 52 week low of $94.55 and a 52 week high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $81,370.00, a P/E ratio of 15.45, a price-to-earnings-growth ratio of 0.76 and a beta of 1.79.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The business had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the prior year, the business earned $1.58 earnings per share. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. equities research analysts expect that Celgene Corporation will post 6.67 EPS for the current year.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.